Cargando…

Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)

PURPOSE: There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to investigate the potential of (18)F-FDG-PET/ CT to predict mortality in IPF. METHODS: A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Win, Thida, Screaton, Nicholas J., Porter, Joanna C., Ganeshan, Balaji, Maher, Toby M., Fraioli, Francesco, Endozo, Raymondo, Shortman, Robert I., Hurrell, Lynn, Holman, Beverley F., Thielemans, Kris, Rashidnasab, Alaleh, Hutton, Brian F., Lukey, Pauline T., Flynn, Aiden, Ell, Peter J., Groves, Ashley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978900/
https://www.ncbi.nlm.nih.gov/pubmed/29335764
http://dx.doi.org/10.1007/s00259-017-3917-8
_version_ 1783327578772209664
author Win, Thida
Screaton, Nicholas J.
Porter, Joanna C.
Ganeshan, Balaji
Maher, Toby M.
Fraioli, Francesco
Endozo, Raymondo
Shortman, Robert I.
Hurrell, Lynn
Holman, Beverley F.
Thielemans, Kris
Rashidnasab, Alaleh
Hutton, Brian F.
Lukey, Pauline T.
Flynn, Aiden
Ell, Peter J.
Groves, Ashley M.
author_facet Win, Thida
Screaton, Nicholas J.
Porter, Joanna C.
Ganeshan, Balaji
Maher, Toby M.
Fraioli, Francesco
Endozo, Raymondo
Shortman, Robert I.
Hurrell, Lynn
Holman, Beverley F.
Thielemans, Kris
Rashidnasab, Alaleh
Hutton, Brian F.
Lukey, Pauline T.
Flynn, Aiden
Ell, Peter J.
Groves, Ashley M.
author_sort Win, Thida
collection PubMed
description PURPOSE: There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to investigate the potential of (18)F-FDG-PET/ CT to predict mortality in IPF. METHODS: A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) were prospectively recruited for (18)F-FDG-PET/CT. The overall maximum pulmonary uptake of (18)F-FDG (SUV(max)), the minimum pulmonary uptake or background lung activity (SUV(min)), and target-to-background (SUV(max)/ SUV(min)) ratio (TBR) were quantified using routine region-of-interest analysis. Kaplan–Meier analysis was used to identify associations of PET measurements with mortality. We also compared PET associations with IPF mortality with the established GAP (gender age and physiology) scoring system. Cox analysis assessed the independence of the significant PET measurement(s) from GAP score. We investigated synergisms between pulmonary (18)F-FDG-PET measurements and GAP score for risk stratification in IPF patients. RESULTS: During a mean follow-up of 29 months, there were 54 deaths. The mean TBR ± SD was 5.6 ± 2.7. Mortality was associated with high pulmonary TBR (p = 0.009), low forced vital capacity (FVC; p = 0.001), low transfer factor (TLCO; p < 0.001), high GAP index (p = 0.003), and high GAP stage (p = 0.003). Stepwise forward-Wald–Cox analysis revealed that the pulmonary TBR was independent of GAP classification (p = 0.010). The median survival in IPF patients with a TBR < 4.9 was 71 months, whilst in those with TBR > 4.9 was 24 months. Combining PET data with GAP data (“PET modified GAP score”) refined the ability to predict mortality. CONCLUSIONS: A high pulmonary TBR is independently associated with increased risk of mortality in IPF patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-017-3917-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5978900
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59789002018-06-21 Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) Win, Thida Screaton, Nicholas J. Porter, Joanna C. Ganeshan, Balaji Maher, Toby M. Fraioli, Francesco Endozo, Raymondo Shortman, Robert I. Hurrell, Lynn Holman, Beverley F. Thielemans, Kris Rashidnasab, Alaleh Hutton, Brian F. Lukey, Pauline T. Flynn, Aiden Ell, Peter J. Groves, Ashley M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to investigate the potential of (18)F-FDG-PET/ CT to predict mortality in IPF. METHODS: A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) were prospectively recruited for (18)F-FDG-PET/CT. The overall maximum pulmonary uptake of (18)F-FDG (SUV(max)), the minimum pulmonary uptake or background lung activity (SUV(min)), and target-to-background (SUV(max)/ SUV(min)) ratio (TBR) were quantified using routine region-of-interest analysis. Kaplan–Meier analysis was used to identify associations of PET measurements with mortality. We also compared PET associations with IPF mortality with the established GAP (gender age and physiology) scoring system. Cox analysis assessed the independence of the significant PET measurement(s) from GAP score. We investigated synergisms between pulmonary (18)F-FDG-PET measurements and GAP score for risk stratification in IPF patients. RESULTS: During a mean follow-up of 29 months, there were 54 deaths. The mean TBR ± SD was 5.6 ± 2.7. Mortality was associated with high pulmonary TBR (p = 0.009), low forced vital capacity (FVC; p = 0.001), low transfer factor (TLCO; p < 0.001), high GAP index (p = 0.003), and high GAP stage (p = 0.003). Stepwise forward-Wald–Cox analysis revealed that the pulmonary TBR was independent of GAP classification (p = 0.010). The median survival in IPF patients with a TBR < 4.9 was 71 months, whilst in those with TBR > 4.9 was 24 months. Combining PET data with GAP data (“PET modified GAP score”) refined the ability to predict mortality. CONCLUSIONS: A high pulmonary TBR is independently associated with increased risk of mortality in IPF patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-017-3917-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-01-16 2018 /pmc/articles/PMC5978900/ /pubmed/29335764 http://dx.doi.org/10.1007/s00259-017-3917-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Win, Thida
Screaton, Nicholas J.
Porter, Joanna C.
Ganeshan, Balaji
Maher, Toby M.
Fraioli, Francesco
Endozo, Raymondo
Shortman, Robert I.
Hurrell, Lynn
Holman, Beverley F.
Thielemans, Kris
Rashidnasab, Alaleh
Hutton, Brian F.
Lukey, Pauline T.
Flynn, Aiden
Ell, Peter J.
Groves, Ashley M.
Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
title Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
title_full Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
title_fullStr Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
title_full_unstemmed Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
title_short Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
title_sort pulmonary (18)f-fdg uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (ipf)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978900/
https://www.ncbi.nlm.nih.gov/pubmed/29335764
http://dx.doi.org/10.1007/s00259-017-3917-8
work_keys_str_mv AT winthida pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT screatonnicholasj pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT porterjoannac pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT ganeshanbalaji pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT mahertobym pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT fraiolifrancesco pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT endozoraymondo pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT shortmanroberti pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT hurrelllynn pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT holmanbeverleyf pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT thielemanskris pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT rashidnasabalaleh pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT huttonbrianf pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT lukeypaulinet pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT flynnaiden pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT ellpeterj pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf
AT grovesashleym pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf